Problems with sense of smell are more frequent and severe in patients with primary progressive multiple sclerosis (PPMS) than in those with relapsing-remitting multiple sclerosis (RRMS), a study reports. The research, “Olfactory dysfunction in patients with primary progressive MS,” was published in the journal Neurology: Neuroimmunology and Neuroinflammation. A distinguishing feature of RRMS, the most common form of the disease, is attacks of new or increasing neurologic symptoms, such as movement disorders, and then recovery periods. About 15 percent of patients have the primary progressive form, or PPMS. Its main feature is gradually increasing neurologic disability without recovery periods. Some scientists believe PPMS is a less inflammatory course of MS. The differences in the processes that underlie each form are not well understood, however. Several researchers think that studying differences in the two groups' ability to smell — or olfactory dysfunction — could shed light on these underlying processes. Autopsies of MS patients in one study showed that 71 percent had experienced demyelination, or loss of neurons, in the brain's olfactory pathway. The processes that led to this dysfunction were unclear, however. Researchers decided to test the hypothesis that olfactory impairment is more pronounced in patients with PPMS than RRMS. The team examined 32 patients with PPMS, 32 with RRMS, and 32 healthy controls. The yardstick they used to evaluate sense of smell was the olfactory Threshold Discrimination Identification (TDI) Test. It involves patients smelling 48 sniffin' sticks. In addition to an overall TDI, there were subscores on olfactory threshold, odor identification and odor discrimination. Olfactory threshold refers to the lowest concentration of an odor that a person can detect. Researchers found olfactory dysfunction in 27, or 84 percent, of the PPMS patients; 10, or 31 percent, of the RRMS patients; and 1, or 3 percent, of the healthy controls. The TDI score and all subscores were significantly worse in patients with PPMS than in the controls, when considering patients of similar age and the same sex. The TDI score was also worse in PPMS patients than in the RRMS group, after adjusting for age, sex, MS disability level, the length of time patients had the disease, and patients' ability to identify and discriminate among odors. Researchers acknowledged limitations to the study. One was the small size of the groups in the research. Another was not using magnetic resonance imaging, or MRI, to measure olfactory pathway deterioration. Comparing the brain's olfactory pathway region with other brain regions in both the RRMS and PPMS groups could have shed light on the processes underlying the olfactory dysfunction differences between the two, researchers said. “The findings suggest that olfactory dysfunction might be a surrogate of neurodegeneration in these patients," the researchers wrote. "Studies correlating olfactory function with radiologic and clinical markers of disease progression would be of interest.”
Patricia Silva, PhD
Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Silva, PhD
The stress of caring for a family member with multiple sclerosis (MS) or another neurodegenerative disease may directly affect the…
TG Therapeutics’ investigational treatment — ublituximab (TG-1101) — led to a near total depletion of B-cells in patients with relapsing forms of…
The Multiple Sclerosis Association of America (MSAA) has released three new resources for people with multiple sclerosis (MS), available for…
Shared decision-making between patients and their doctors and healthcare providers was considered a critical step in the process of treating …
Catheterization training in the hospital did not prepare me for how to manage on a daily basis. In my…
AXIM Biotechnologies has secured an additional $4 million in institutional financing to advance clinical trials of its cannabinoid therapies for multiple…
The National Multiple Sclerosis (MS) Society has selected research highlights from a recent MS conference in an effort to help make living with…
Researchers managed to change the immune system — replacing inflammation with immune tolerance — in a mouse model of multiple…
Unpublished Data May Point to Link Between Lemtrada and Other Autoimmune Diseases in MS Patients
Previously unpublished results of clinical trials of Lemtrada (alemtuzumab) appears to contain key information as to why many multiple sclerosis patients…
The National Multiple Sclerosis Society and a dozen other advocacy groups have banded together to support the Air Carrier Access…
The Maccabees rock band will play an exclusive gig in London to raise funds for the United Kingdom’s MS…
A high daily dose of simvastatin improves multiple sclerosis patients’ cognitive function, according to a new analysis of Phase 2 clinical…
Already an approved treatment for relapsing and primary progressive multiple sclerosis (MS), Ocrevus (ocrelizumab) is still undergoing scrutiny in several…
Bringing More Minority MS Patients into Research Is Project’s Goal, Starting with 15-Minute Survey
The MS Minority Research Engagement Partnership Network is calling for all multiple sclerosis (MS) patients, ages 21 and older,…
Catheterization was one of my biggest fears when first officially diagnosed with MS in 1994. As the years…
Ocrevus (ocrelizumab), a recently approved therapy for relapsing and primary progressive multiple sclerosis (MS), is now on the U.S. market, but…
How multiple sclerosis affects the “social brain,” which governs the ability to understand how others think and feel — a skill…
The U.S. Food and Drug Administration has approved a supplemental biologics license application for two Bayer products that help multiple…
The recent annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) brought researchers and healthcare professionals to New Orleans to discuss…
To honor World MS Day, May 31, EMD Serono launched a multiple sclerosis care partner survey in collaboration with the…
Mallinckrodt Enrolls First Patient in Acthar Gel Clinical Trial for Relapsing Multiple Sclerosis
Mallinckrodt has enrolled its first relapsing multiple sclerosis (MS) patient into a Phase 4 clinical trial (NCT03126760) with …
Today is World MS Day, and people around the world are sharing tips for living with multiple sclerosis (MS) by…
The casual remark, “You seem perfectly fine to me!” bothers me (and others) because eligibility for Social Security Disability benefits requires…
Multiple sclerosis patients who start Rituxan (rituximab) treatment are three times more likely to have unchanged or improved brain-scan readings…
#CMSC17 – Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments
Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after…
Patients must help develop new outcome measures of multiple sclerosis (MS), since they and healthcare providers may have differing perceptions of…
People with multiple sclerosis (MS) who feel stigmatized because of their condition are more likely to have depression, research presented…
#CMSC17 – Relapse After First Lemtrada Course No Indication of Poor Long-Term Outcome, Study Finds
Multiple sclerosis (MS) patients who experienced a relapse between their first and second rounds of Lemtrada (alemtuzumab) had good treatment…
Genentech has rolled out a website to connect multiple sclerosis (MS) patients and caregivers with resources that can help…